Parker Waichman LLP has filed a lawsuit alleging that Plavix caused three episodes of gastrointestinal hemorrhaging in a Tennessee woman. The suit was filed in the Supreme Court of the State of New York, County of New York and names Bristol-Myers Squibb Company, Sanofi-Aventis U.S., L.L.C., Sanofi US Services Inc., and Sanofi-Synthelabo, Inc. as defendants
According to the lawsuit, the woman began taking Plavix in April 2011. Thereafter, she suffered three gastrointestinal hemorrhages, most recently in September 2011. The lawsuit alleges that Plavix caused the multiple bleeding episodes and holds the defendants responsible for making misleading statements about the safety of the medication.
As a result of these conditions, the suit alleges that the woman has suffered severe and permanent injuries, physical impairment and disfigurement, physical pain and suffering, mental pain and suffering and loss of enjoyment of life. The lawsuit also states that the woman has incurred and will continue to incur various sums of money due to past, present and future medical expenses associated with her injuries.
Among other things, the defendants are accused of unethical business practices with regards to marketing Plavix, which was approved to prevent atherosclerotic events in high risk patients. The suit points out that its approval was based on a single study comparing the medication to Aspirin, known as CAPRIE. According to the lawsuit, the defendants marketed Plavix in direct defiance to the FDA, who stated that Plavix should not replace Aspirin as a first-line therapy for preventing ischemic events.
According to the lawsuit, the defendants touted Plavix as “super-aspirin” in order to protect their financial interests. Despite the defendants’ claims, the lawsuit cites a number of research studies that suggest the Aspirin is equally, if not more, beneficial than Plavix in certain patients.